

Result No.	Score	Query Match	Length	DB ID	Description
1	65	100.0	13	AAH82037	Human heptareceptor
2	65	100.0	34	AAH82020	Human heptareceptor
3	65	100.0	436	AAV73954	Human color: cancer
4	65	100.0	566	AAV27443	Amino acid sequen
5	65	100.0	622	AAV30004	Novel human secret
6	65	100.0	635	AAH53356	Human color: cancer
7	60	92.3	12	AAH82038	Human heptareceptor
8	57	87.7	52	AAU33060	Novel human secret
9	55	84.6	11	AAH82039	Human heptareceptor
10	41	63.1	27	AAV27444	Antigen-mediated inte

XX Novel regulatory or unfolding peptides of ezrin that binds to  
 PT heprecceptor, useful for inducing immune response for treating  
 PT infectious diseases and cancer -  
 XX  
 PS Claim 22; Page 46; 42pp; English.  
 XX  
 CC The heprecceptor is a novel active site in human ezrin. Ezrin regulates  
 CC the structure of the cortical cytoskeleton to control cell surface  
 CC topography. The present invention relates to peptides (see AAB82021 to  
 CC AAB82041) that bind to heprecceptor with greater affinity than HEP1 (see  
 CC AAB82046). The heprecceptor binding peptides are useful for inducing  
 CC immune response, and for treating infectious diseases, cancer and  
 CC HIV-related dementia. The present peptide binds to domain A of the  
 CC heprecceptor (AAB82019).  
 XX  
 SQ Sequence 13 AA;  
 Query Match 100.0%; Score 65; DR 22; Length 13;  
 Best Local Similarity 100.0%; Pred. NO. 0.00055;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KEELMLRLQDYEE 13  
 DB 1 KEELMLRLQDYEE 13  
 RESULT 2  
 AAB82020  
 ID AAB82020 standard; peptide; 34 AA.  
 AC AAB82020;  
 XX  
 DT 13-JUN 2001 (first entry)  
 XX  
 DE Human heprecceptor domain H.  
 XX  
 KW Human; heprecceptor domain H; cytostatic; anti-HIV; antibiotic;  
 KW neurotropic; immune response inducer; ezrin; infectious diseases; cancer;  
 KW HIV-related dementia.  
 XX  
 OS Homo sapiens.  
 XX  
 PN KEY location/qualifiers  
 PH Modified-site 14  
 FT /note- "optionally phosphorylated"  
 XX  
 PN GB2454241-A.  
 XX  
 PD 21-MAR 2001.  
 XX  
 PF 17-SEP-1999; 99GB-0021881.  
 XX  
 PR 17-SEP-1999; 99GB-0021881.  
 XX  
 PA (HOLM/) HOLMS R D.  
 XX  
 PI Holms RD;  
 XX  
 DR WPI: 2001 291287/31  
 XX  
 PT Novel regulatory or unfolding peptides of ezrin that binds to  
 PT heprecceptor, useful for inducing immune response for treating  
 PT infectious diseases and cancer -  
 PS Claim 5; Page 46; 42pp; English.  
 XX  
 CC The present sequence is domain H of human heprecceptor of human ezrin. The  
 CC heprecceptor is a novel active site in human ezrin. Ezrin regulates the  
 CC structure of the cortical cytoskeleton to control cell surface  
 CC topography. The present invention relates to peptides (see AAB82021 to  
 CC AAB82041) that bind to heprecceptor with greater affinity than HEP1 (see  
 CC AAB82046). The heprecceptor binding peptides are useful for inducing

CC immune response, and for treating infectious diseases, cancer and  
 CC HIV related dementia. The present sequence assembles into two  
 CC anti-parallel helices with heprecceptor domain A (see AAB82019).  
 XX  
 SQ Sequence 34 AA;  
 Query Match 100.0%; Score 65; DR 22; Length 34;  
 Best Local Similarity 100.0%; Pred. NO. 0.0015;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KEELMLRLQDYEE 13  
 DB 4 KEELMLRLQDYEE 16  
 RESULT 3  
 AAG73954  
 ID AAG73954 standard; protein; 436 AA.  
 XX  
 AC AAG73954;  
 XX  
 DT 03-SEP-2001 (first entry)  
 XX  
 DE Human colon cancer antigen protein SEQ ID NO:4718.  
 XX  
 KW Human; colon cancer; colon cancer antigen; diagnosis; detection;  
 KW colorectal carcinoma.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200122923-A2.  
 XX  
 PD 05-APR-2001.  
 XX  
 PF 28-SEP-2000; 2000W0-US26524.  
 XX  
 PR 29-SEP-1999; 99US-0157147.  
 PP 03-NOV-1999; 99US-0163280.  
 XX  
 PA (HOMA-) HUMAN GENOME SCI INC.  
 XX  
 PI Ruben SM, Harash SC, Birse CE, Rosen CA.  
 XX  
 DR WPI: 2001 235357/24.  
 DR N-PSDB: AAB33385.  
 XX  
 PT Nucleic acids encoding 4277 human colon cancer-associated polypeptides,  
 PT useful for preventing, diagnosing and/or treating colorectal cancers -  
 XX  
 PS Claim 11; Page 6526 6521; 9803pp; English.  
 XX  
 CC AAB32043 to AAB37105 and AAG73514 to AAG77788 represent human colon  
 CC cancer-associated nucleic acid molecules (N) and proteins (P), where  
 CC the proteins are collectively known as colon cancer antigens. The colon  
 CC cancer antigens have cytostatic activity and can be used in gene  
 CC therapy and vaccine production. N and P may be used in the prevention,  
 CC diagnosis and treatment of diseases associated with inappropriate P  
 CC expression. For example, N and P may be used to treat disorders  
 CC associated with decreased expression by rectifying mutations or deletions  
 CC in a patient's genome that affect the activity of P by expressing  
 CC inactive proteins or to supplement the patients own production of P.  
 CC Additionally, N may be used to produce the colon cancer-associated PS,  
 CC by inserting the nucleic acids into a host cell and culturing the cell  
 CC to express the proteins. N and P can be used in the prevention, diagnosis  
 CC and treatment of colorectal carcinomas and cancers. AAB37196 to AAB7204  
 CC and AAB77789 represent sequences used in the exemplification of the  
 CC present invention.  
 CC N.R. Pages 666 to 682 and page 7053 of the sequence listing were  
 CC missing at time of publication, meaning no sequences are present for  
 CC SEQ ID Nos:1057 to 1052, 7021 and 7022.  
 XX  
 SQ Sequence 436 AA;

```

Query Match      100.0%; Score 65; DB 20; Length 436;
Best Local Similarity 100.0%; Pred. No. 0.02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KEELMLRLQDYEE 13
DB 194 KEELMLRLQDYEE 206
|||||

RESULT 4
AAV27443
ID AAY27443 standard; protein; 586 AA.
XX AC AAY27443;
XX DT 26-NOV-1999 (first entry)
DE Amino acid sequence of human ezrin polypeptide.
XX KW Pharmaceutical; ezrin; mutant; tumor; metastasis, human.
XX OS Homo sapiens.
XX PH Key Location/Qualifiers
FT Misc-difference 354
FT /note= "the Tyr at this position can be mutated
FT (preferably to a Phe) to construct an
FT ezrin mutant of the invention"
XX PN W09947150-A2.
XX PD 23-SEP-1999.
XX PF 18-MAR-1999; 99WO-EP02054.
XX PR 18-MAR-1999; 98US-0040725.
XX PA (CURL-) INST CUIP.
XX PA (CNRS) CNRS CENT NAT RECH SCI.
XX PI Arpin M, Crepaldi T, Gautreau A, Louvard D;
XX WP1; 1999-561851/47.
XX DR New composition for prevention and treatment of tumors and metastasis
XX PT
XX PS Example 1; Fig 1; 31pp; English.
XX CC The invention provides a pharmaceutical composition containing ezrin
XX protein, RNA or DNA mutated on tyrosine 353, or a functional fragment
XX or derivative of the ezrin mutant. The new composition is useful for
XX prevention and/or treatment of tumors, and especially metastasis. The
XX present sequence represents the amino acid sequence of human ezrin
XX (before the maturation by deletion of the first amino acid Met).
XX SQ Sequence 586 AA;

Query Match      100.0%; Score 65; DB 20; Length 586;
Best Local Similarity 100.0%; Pred. No. 0.027;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KEELMLRLQDYEE 13
DB 344 KEELMLRLQDYEE 356
|||||

RESULT 5
AAU30004
ID AAU30004 standard; Protein; 622 AA.
XX AC AAU30004;
XX KW nephrotropic; antiinfective; antibacterial; gene therapy, wound;
XX
```

```

DE 18-DIC-2001 (first entry)
XX Novel human secreted protein #495.
XX Human, vaccination, gene therapy, nutritional supplement;
KW stem cell proliferation, haematopoiesis, nerve tissue regeneration;
KW immune suppression, immune stimulation, anti-inflammatory, leukaemia.
XX OS Homo sapiens.
XX PN W0200179449-A2.
XX PD 25-OCT-2001.
XX PF 16-APR-2001; 2001WO-US08656.
XX PP 18-APR-2000; 2000NS-0557929.
XX PR 25 JAN. 2001; 2001US-0770160.
XX PA (HYSE-) HYSEQ INC.
XX PI Tanq YT, Liu C, Drmanac RT;
XX WP1; 2001-611725/70.
XX PT Nucleic acids encoding a range of human polypeptides, useful in genetic
XX vaccination, testing and therapy -
XX PS Claim 20; Page 219; 765pp; English.
XX CC The invention relates to novel human secreted polypeptides. The
XX polypeptides and antibodies to the polypeptides are useful for
XX determining the presence of or predisposition to a disease associated
XX with altered levels of polypeptide. The polypeptides are also useful for
XX identifying agents (agonists and antagonists) that bind to them. Cells
XX expressing the proteins are useful for identifying a therapeutic agent
XX for use in treatment of a pathology related to aberrant expression or
XX physiological interactions of the polypeptide. Vectors comprising
XX the nucleic acids encoding the polypeptides and cells genetically
XX engineered to express them are also useful for producing the proteins.
XX The proteins are useful in genetic vaccination, testing and
XX therapy, and can be used as nutritional supplements. They may be used to
XX increase stem cell proliferation; to regulate haematopoiesis; and in
XX bone, cartilage, tendon and/or nerve tissue growth or regeneration;
XX immune suppression and/or stimulation; as anti-inflammatory agents; and
XX in treatment of leukaemias. AAU29510-AAU33304 represent the amino acid
XX sequences of novel human secreted proteins of the invention.
XX SQ Sequence 622 AA;

Query Match      100.0%; Score 65; DB 22; Length 622;
Best Local Similarity 100.0%; Pred. No. 0.029;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KEELMLRLQDYEE 13
DB 380 KEELMLRLQDYEE 392
|||||

RESULT 6
AAH53356
ID AAH53356 standard; Protein; 635 AA.
XX AC AAH53356;
XX DT 09-MAR-2001 (first entry)
XX DE Human colon cancer antigen protein sequence Sbg II No:896.
XX KW Human, colon cancer, colon cancer antigen; diagnosis; detection;
KW identification; cytostatic; cardioactive; neuroprotective; vulnary;
KW immunomodulatory; muscular; gynaecological; gastrointestinal;
KW nephrotropic; antiinfective; antibacterial; gene therapy, wound;
```

KW neutral disorder; immune system disorder; muscular disorder;  
 KW reproductive disorder; gastrointestinal disorder; renal disorder;  
 KW infectious disease; cardiovascular disorder.  
 XX Homo sapiens.  
 OS  
 XX W0200055451-A1.  
 PN  
 XX  
 XX  
 PD  
 XX  
 XX  
 PD 21-SEP-2000.  
 XX  
 XX 08 MAR-2000; 2006W0-0505884.  
 PF  
 XX  
 XX 12 MAR-1999; 9902-0124279.  
 PR  
 XX  
 XX (HUMAN) HUMAN GENOME SCI INC.  
 PA  
 XX  
 XX Rosen CA, Ruben SM.  
 PI  
 XX  
 XX WPI; 2000-587534/55.  
 DR  
 XX N-PSDB; AAC98114.  
 XX  
 XX Colon cancer associated gene sequences, referred to as colon cancer  
 PT antitoxins, useful for the treatment, prevention, and diagnosis of colon  
 PT disorders such as colon cancer.  
 PI  
 XX  
 XX Claim 11: Page 1446-1451; 2104pp; English.  
 PS  
 XX AAC97991 to AAC98763 encode the human colon cancer associated proteins,  
 CC called human colon cancer antigens, given in AAC95314 to AAC94006. The  
 CC human colon cancer antigens can have cytostatic, cardiocactive, muscular;  
 CC neuroprotective, immunomodulatory, gynaecological, gastrointestinal,  
 CC uinary, nephrotropic, antineoplastic and antibacterial activities, and  
 CC can be used in gene therapy. The colon cancer antigen polynucleotides,  
 CC proteins and antibodies to the proteins are useful for the prevention,  
 CC treatment and diagnosis of colon disorders, such as colon cancer. The  
 CC polynucleotides may be used in diagnostics and research, such as for  
 CC chromosome identification, and as hybridisation probes. The proteins  
 CC may also be used to prevent diseases such as neural disorders, immune  
 CC system disorders, muscular disorders, reproductive disorders,  
 CC gastrointestinal disorders, wounds, renal disorders, infectious  
 CC diseases, and cardiovascular disorders. AAC98764 to AAC98772 and  
 CC AAC94007 represent sequences used in the exemplification of the present  
 CC invention.  
 XX  
 XX  
 SQ Sequence 635 AA:  
 Query Match 100.0%; Score 65; DB 21; Length 635;  
 Best Local Similarity 100.0%; Pred. No. 0.03;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 KEELMLRLQDYEE 14  
 DB 494 KEELMLRLQDYEE 405  
 |||||  
 RESULT 7  
 AA082038  
 ID AA082038 standard; peptide: 12 AA.  
 AC AA082038;  
 XX  
 XX 13-JUN 2001 (first entry)  
 DE Human hepreceptor domain A binding peptide Rnp2132.  
 XX  
 XX Human; hepreceptor; cytostatic; anti-HIV; antibiotic;  
 KW neoplastic; immune response inducer; ezrin; infectious diseases; cancer;  
 KW HIV-related dementia.  
 KW  
 XX Homo sapiens.  
 OS  
 XX  
 XX Key Location/Analysfiers  
 PI Modified site 10  
 PI

/note- "Optionally phosphorylated"  
 FI  
 XX GB2354241-A.  
 PN  
 XX 21-MAR-2001.  
 PD  
 XX  
 XX 17-SEP-1999; 99GH-0021881.  
 PP  
 XX  
 XX 17-SEP-1999; 99GH-0021881.  
 PR  
 XX (HOLM/J HOLMS R D.  
 PA  
 XX Holms RD;  
 PI  
 XX WPI; 2001-293287/41.  
 DR  
 XX  
 XX Novel regulatory or untolding peptides of ezrin that binds to  
 PT hepreceptor, useful for inducing immune response for treating  
 PT infectious diseases and cancer.  
 PI  
 XX  
 XX Claim 24; Page 36; 42pp; English.  
 PS  
 XX The hepreceptor is a novel active site in human ezrin. Ezrin regulates  
 CC the structure of the cortical cytoskeleton to control cell surface  
 CC topography. The present invention relates to peptides (see AA082021 to  
 CC AA082041) that bind to hepreceptor with greater affinity than HEP1 (see  
 CC AA082046). The hepreceptor binding peptides are useful for inducing  
 CC immune response, and for treating infectious diseases, cancer and  
 CC HIV-related dementia. The present peptide binds to domain A of the  
 CC hepreceptor (AA082019).  
 XX  
 XX Sequence 12 AA:  
 SQ  
 Query Match 92.3%; Score 60; DB 22; Length 12;  
 Best Local Similarity 100.0%; Pred. No. 0.032;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 2 EELMLRLQDYEE 13  
 DB 1 EELMLRLQDYEE 12  
 |||||  
 RESULT 8  
 AA033060  
 ID AA033060 standard; Protein: 52 AA.  
 AC AA033060;  
 XX  
 XX 18-DEC-2001 (first entry)  
 DE Novel human secreted protein #3551.  
 XX  
 XX Human; vaccination; gene therapy; nutritional supplement;  
 KW stem cell; proliferation; haematopoiesis; nerve tissue regeneration;  
 KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.  
 KW  
 XX Homo sapiens.  
 OS  
 XX W0200179449-A2.  
 PN  
 XX  
 XX 25-OCT-2001.  
 PD  
 XX  
 XX 16-APR-2001; 2001W0-0508656.  
 PF  
 XX  
 XX 18-APR-2000; 2000US-052929.  
 PR  
 XX 26-JAN-2001; 2001US-0770160.  
 PP  
 XX (HYPSE-) HYPSE INC.  
 PA  
 XX  
 XX Tang YT, Liu C, Drmanac RT;  
 PI  
 XX WPI; 2001-611725/70.  
 DR  
 XX

PT Nucleic acids encoding a range of human polypeptides, useful in genetic  
 PT vaccination, testing and therapy -  
 PS Claim 20; Page 702; 765pp; English  
 XX The invention relates to novel human secreted polypeptides. The  
 CC polypeptides and antibodies to the polypeptides are useful for  
 CC determining the presence of or predisposition to a disease associated  
 CC with altered levels of polypeptide. The polypeptides are also useful for  
 CC identifying agents (agonists and antagonists) that bind to them. Cells  
 CC expressing the proteins are useful for identifying a therapeutic agent  
 CC for use in treatment of a pathology related to aberrant expression or  
 CC physiological interactions of the polypeptide. Vectors comprising  
 CC the nucleic acids encoding the polypeptides and cells genetically  
 CC engineered to express them are also useful for producing the proteins.  
 CC The proteins are useful in genetic vaccination, testing and  
 CC therapy, and can be used as nutritional supplements, they may be used to  
 CC increase stem cell proliferation; to regulate haematopoiesis; and in  
 CC bone, cartilage, tendon and/or nerve tissue growth or regeneration;  
 CC immune suppression and/or stimulation; as anti-inflammatory agents; and  
 CC in treatment of leukaemias. AA029510-AA03304 represent the amino acid  
 CC sequences of novel human secreted proteins of the invention.  
 XX  
 SQ Sequence 52 AA;

Query Match 87.7%; Score 57; DP 22; Length 52;  
 Best Local Similarity 92.3%; Pred. No. 0.043;  
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 KEELMLRLQDYEE 13  
 Db 12 KEELMLRLQDYEE 24

RESULT 9  
 AAB82039  
 ID AAB82039 standard; peptide; 11 AA.

XX AAB82039;

XX 13-JUN-2001 (first entry)

XX Human hepreceptor domain A binding peptide Eupc2232.

XX Human, hepreceptor, cytostatic, anti-HIV; antibiotic;  
 KW neotropic, immune response inducer, ezrin, infectious diseases, cancer;  
 KW HIV-related dementia.

XX Homo sapiens.

XX Key Location/Qualifiers

FT Modified-site 9 /note- "Optionally phosphorylated"

FT FT

PN GB2354241-A.

XX 21-MAR-2001.

XX 17-SEP-1999; 99GB-0021881.

XX 17-SEP-1999; 99GB-0021881

XX (HOLM/) HOLMS R D.

XX Holms RD;

XX WPI: 2001 293287/31.

XX Novel regulatory or cofolding peptides of ezrin that binds to  
 PT hepreceptor, useful for inducing immune response for treating  
 PT infectious diseases and cancer -  
 XX

PS Claim 26; Page 37; 42pp; English.

XX The hepreceptor is a novel active site in human ezrin. Ezrin regulates  
 CC the structure of the cortical cytoskeleton to control cell surface  
 CC topography; the present invention relates to peptides (see AAB82039 to  
 CC AAB82041) that bind to hepreceptor with greater affinity than HMP1 (see  
 CC AAB82046). The hepreceptor binding peptides are useful for inducing  
 CC immune response, and for treating infectious diseases, cancer and  
 CC HIV-related dementia. The present peptide binds to domain A of the  
 CC hepreceptor (AAB82019).

SQ Sequence 11 AA;

Query Match 84.6%; Score 55; DP 22; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 0.018;  
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 ELMRLQDYEE 13

Db 1 ELMRLQDYEE 11

RESULT 10

AAV27444

ID AAV27444 standard; peptide; 27 AA.

XX AAV27444;

XX 26-NOV-1999 (first entry)

XX Antennapedia internalization sequence in tandem with ezrin fragment.

XX Pharmacological, ezrin, mutant, tumor, antennapedia internalization;  
 KW metastasis; human.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 1 /note- "biotinylated"

FT Modified-site 22

FT /note "Optionally phosphorylated"

XX W99947150 A2.

XX 23-SEP-1999.

XX 18-MAR-1999; 99WO-EP02054.

XX 18-MAR-1998; 98CS-0040725.

XX (CURT-) INST CURT.

XX (CNRS ) CNRS CENT NAT RECH SCI.

XX Arpin M, Crepaldi T, Gautreau A, Louvard D;

XX WPI: 1999-561851/47.

XX New composition for prevention and treatment of tumors and metastasis  
 FT

XX Example 5; Page 14; 31pp; English.

XX The invention provides a pharmacological composition containing ezrin  
 CC protein, RNA or DNA mutated on tyrosine 353, or a functional fragment  
 CC or derivative of the ezrin mutant. The new composition is useful for  
 CC prevention and/or treatment of tumors, and especially metastasis. The  
 CC present sequence represents an antennapedia internalization sequence in  
 CC tandem with an ezrin fragment (residues 348-358). This is used in  
 CC experiments of p85 interaction with phosphorylated ezrin peptides.

SQ Sequence 27 AA;

Query Match 63.1%; Score 41; DP 20; Length 27;

Best Local Similarity 100.0%; Pred. No. 7.7;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 LKLMRLQDYE 13  
DB 17 LKLMRLQDYE 24

RESULT 11  
ABG29165  
ID ABG29165 standard; Protein: 344 AA.  
XX  
AC ABG29165;  
XX

DI 13-FEB-2002 (first entry)  
DE Novel human diagnostic protein #29156.  
XX

KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
KW food supplement; medical imaging; diagnostic; genetic disorder.  
XX  
XX Homo sapiens.  
OS

PN W0200175067-A2.  
XX  
XX 11-OCT 2001.  
XX

DI 30-MAR-2001; 2001WO-US0864;  
XX  
XX 31-MAR-2001; 2001WO-US0864;  
XX  
XX 23-AUG-2001; 2001US-0649167  
XX

PA (HVSF) HYSEQ INC.  
PI Brnmanac Rd, Lin C, Lang YI;  
XX  
XX WPI: 2001-483447/52.  
XX  
XX N-PSDB: AAS93352.

PI New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity.

PS Claim 20; SEQ ID No 59524; 103pp; English.

CC The invention relates to isolated polynucleotide (I) and  
CC polypeptide (II) sequences (I) is useful as hybridisation probes,  
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
CC and gene mapping, and in recombinant production of (II). The  
CC polynucleotides are also used in diagnostics as expressed sequence tags  
CC for identifying expressed genes. (I) is useful in gene therapy techniques  
CC to restore normal activity of (I) or to treat disease states involving  
CC (II). (II) is useful for generating antibodies against it, detection or  
CC quantitating a polypeptide in tissue, as molecular weight markers and as  
CC a food supplement. (II) and its binding partners are useful in medical  
CC imaging of sites expressing (II). (I) and (II) are useful for treating  
CC disorders involving aberrant protein expression or biological activity.  
CC The polypeptide and polynucleotide sequences have applications in  
CC diagnostics, forensics, gene mapping, identification of mutations  
CC responsible for genetic disorders or other traits to assess biodiversity  
CC and to produce other types of data and products dependent on DNA and  
CC amino acid sequences. ABG00010-ABG0377 represent novel human  
CC diagnostic amino acid sequences of the invention.

CC Note: The sequence data for this patent did not appear in the printed  
CC specification, but was obtained in electronic format directly from WIPo  
CC at ftp.wipo.int/pub/published\_pct\_sequences.

XX Sequence 344 AA;  
XX  
XX Query Match: 63.1%; Score 41; DB 22; Length 344;  
XX Best Local Similarity 72.7%; Pred. No. 1e+02;  
XX Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2 BELMLRLQDYE 12  
DB 278 KKLMLRLQDYE 288

RESULT 12  
ABH42735  
ID ABH42735 standard; Peptide: 46 AA.  
XX  
AC ABH42735;  
XX

DI 04-FEB-2002 (first entry)  
DE Peptide #10241 encoded by human foetal liver single exon probe.  
XX

KW Human, foetal; liver; gene expression; single exon nucleic acid probe.  
XX  
XX Homo sapiens.  
OS

PN W0200157277-A2.  
XX  
XX 09-AUG-2001.  
XX

DI 30-JAN-2001; 2001WO-US00669.  
XX  
XX 04-FEB-2001; 2000US-0180312.  
XX  
XX 26-MAY-2001; 2000US-0207456.  
XX  
XX 30-JUN-2001; 2000US-0608408.  
XX

TE 03-AUG-2001; 2000US-0632366.  
XX  
XX 21-SEP-2001; 2000US-0214687.  
XX  
XX 27-SEP-2001; 2000US-0216359.  
XX  
XX 04-OCT-2001; 2000US-0214263.  
XX

PA (MOLE-) MOLECULAR DYNAMICS INC.  
XX  
XX Fern SG, Hanzel DK, Chen W, Rank DR;  
XX  
XX WPI: 2001-483447/52.  
XX

PI Human genome-derived single exon nucleic acid probes useful for  
PT analyzing gene expression in human foetal liver.

PS Claim 27; SEQ ID No 35370; 639pp + sequence listing; English.

CC The invention relates to a single exon nucleic acid probe for  
CC measuring human gene expression in a sample derived from human foetal  
CC liver. The single exon nucleic acid probes may be used for prediction,  
CC measuring and displaying gene expression in samples derived from human  
CC foetal liver. The present sequence is a peptide encoded by a single exon  
CC nucleic acid probe of the invention.  
CC Note: The sequence data for this patent did not form part of the  
CC printed specification, but was obtained in electronic format directly  
CC from WIPo at ftp.wipo.int/pub/published\_pct\_sequences.

XX Sequence 46 AA;  
XX  
XX Query Match: 61.5%; Score 40; DB 22; Length 46;  
XX Best Local Similarity 53.8%; Pred. No. 19;  
XX Matches 7; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1 KEELMLRLQDYE 13  
DB 31 KKLMLRLQDYE 43

RESULT 13  
AAM63626  
ID AAM63626 standard; Protein: 46 AA.  
XX  
XX AAM63626;  
XX  
XX 05-NOV-2001 (first entry)  
XX



Pr 23 AUG-2000; 2000US 0649167.  
 XX (HYSEQ) HYSEQ INC.  
 XX  
 XX Drmanac RT, Liu C, Tang YF;  
 XX WPI: 2001-639462/73.  
 DR N-PSDB; AAS84134.  
 XX  
 PT New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, forensics, gene mapping, identification of mutations  
 PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity.  
 XX  
 PS Claim 20; SEQ ID No 50406; 103pp; English.  
 XX  
 CC The invention relates to isolated polynucleotide (I) and  
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,  
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
 CC and gene mapping, and in recombinant production of (II). The  
 CC polynucleotides are also used in diagnostics as expressed sequence tags  
 CC for identifying expressed genes. (I) is useful in gene therapy techniques  
 CC to restore normal activity of (II) or to treat disease states involving  
 CC (II). (II) is useful for generating antibodies against it, detecting or  
 CC quantitating a polypeptide in tissue, as molecular weight markers and as  
 CC a food supplement. (II) and its binding partners are useful in medical  
 CC imaging of sites expressing (II). (I) and (II) are useful for treating  
 CC disorders involving aberrant protein expression or biological activity.  
 CC The polypeptide and polynucleotide sequences have applications in  
 CC diagnostics, forensics, gene mapping, identification of mutations  
 CC responsible for genetic disorders or other traits to assess biodiversity  
 CC and to produce other types of data and products dependent on DNA and  
 CC amino acid sequences. AAG00010-AAG30377 represent novel human  
 CC diagnostic amino acid sequences of the invention.  
 CC Note: The sequence data for this patent did not appear in the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at [http://wipo.int/pub/published\\_pat\\_sequences](http://wipo.int/pub/published_pat_sequences).

XX Sequence 593 AA;

Query Match 61.5%; Score 40; DH 22; Length 593;

Best Local Similarity 69.2%; Pred. No. 2.6e+02;

Matches 9; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 KEELMERKQYEE 13

|||||||

Db 359 KEELMERKQYEE 371

Search completed: January 16, 2003, 16:49:14

Job time : 62.8429 secs